DENVER--(BUSINESS WIRE)--Dec. 21, 2005--Studies presented at the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy (“ICAAC”) demonstrated that Ceragenix Pharmaceuticals, Inc.'s (“Ceragenix” or the “Company”) (OTCBB: CGXP) investigational antibacterial CSA-13 showed an excellent microbiology profile in laboratory studies against vancomycin resistant staph aureus (“VRSA”), vancomycin intermediate resistant staph aureus strains (“VISA”), vancomycin resistant erterococci (“VRE”), community associated methicillin-resistant staph aureus (“CA-MRSA”) and hospital acquired MRSA, as well as key gram negative pathogens such as pseudomonas aueroginosa and E. Coli, and bioterrorism surrogate strains for anthrax, listeria and plague. Researchers who contributed to the presentations include Peter Appelbaum (Hershey Medical Center), Henry Chambers (San Francisco General Hospital), Ron Jones (JMI Laboratories) and Paul Savage (BYU). Copies of the poster presentations may be downloaded by going to the Company’s website: www.ceragenix.com.
